Skip to main content

Table 3 Association analysis of rs7044343 with RA in the validation population

From: Genetic variant in IL33 is associated with susceptibility to rheumatoid arthritis

Characteristic ( n)

Allele frequency (%)

Genotype frequency (%)

T vs. C

CC vs. TT + TC

CC + TC vs. TT

T

C

TT

TC

CC

OR (95% CI)

OR (95% CI)

OR (95% CI)

P value

P value

P value

Control (456)

409 (44.8)

503 (55.2)

100 (21.9)

209 (45.8)

147 (32.2)

   

RA (586)

548 (46.8)

624 (53.2)

118 (20.1)

312 (53.2)

156 (26.6)

1.080

0.763

1.114

(0.908-1.285)

(0.583-0.998)

(0.825-1.504)

0.385

0.048*

0.480

RF + (354)

322 (45.5)

386 (54.5)

67 (18.9)

188 (53.1)

99 (28.0)

1.026

0.816

1.203

(0.842-1.250)

(0.602-1.106)

(0.851-1.701)

0.799

0.190

0.295

RF- (98)

100 (51.0)

96 (49.0)

25 (25.5)

50 (51.0)

23 (23.5)

1.281

0.645

0.820

(0.941-1.745)

(0.388-1.070)

(0.495-1.360)

0.116

0.089

0.442

ACPA + (281)

257 (45.7)

305 (54.3)

51 (18.1)

155 (55.2)

75 (26.7)

1.036

0.765

1.267

(0.839-1.280)

(0.551-1.064)

(0.870-1.845)

0.741

0.111

0.217

ACPA- (92)

94 (51.1)

90 (48.9)

21 (22.8)

52 (56.5)

19 (20.7)

1.284

0.547

0.950

(0.935-1.764)

(0.318-0.940)

(0.556-1.622)

0.121

0.029*

0.850

Female control (363)

319 (43.9)

407 (56.1)

75 (20.7)

169 (46.6)

119 (32.8)

   

Female RA (441)

413 (46.8)

469 (53.2)

87 (19.7)

239 (54.2)

115 (26.1)

1.124

0.723

1.060

(0.922-1.369)

(0.533-0.982)

(0.750-1.497)

0.247

0.038

0.743

Female RF+ (291)

264 (45.4)

318 (54.6)

53 (18.2)

158 (54.3)

80 (27.5)

1.059

0.777

1.169

(0.851-1.319)

(0.554-1.090)

(0.791-2.730)

0.607

0.144

0.433

Female RF- (75)

77 (51.3)

73 (48.7)

20 (26.7)

37 (49.3)

18 (24.0)

1.346

0.648

0.716

(0.946-1.914)

(0.365-1.149)

(0.404-1.268)

0.098

0.137

0.252

Female ACPA+ (234)

217 (46.4)

251 (53.6)

43 (18.4)

131 (56.0)

60 (25.6)

1.103

0.707

1.157

(0.873-1.393)

(0.490-1.020)

(0.762-1.755)

0.410

0.064

0.494

Female ACPA- (73)

74 (50.7)

72 (49.3)

18 (24.7)

38 (52.1)

17 (23.3)

1.311

0.622

0.796

(0.919-1.872)

(0.347-1.118)

(0.441-1.435)

0.135

0.112

0.448

Male CON (89)

86 (48.3)

92 (51.7)

24 (27.0)

38 (42.7)

27 (30.3)

   

Male RA (102)

98 (48.0)

106 (52.0)

23 (22.5)

52 (51.0)

27 (26.5)

0.956

0.827

1.268

(0.615-1.486)

(0.440-1.553)

(0.656-2. 452)

0.840

0.554

0.480

Male RF+ (63)

58 (46.0)

68 (54.0)

14 (22.2)

30 (47.6)

19 (30.2)

0.827

0.992

1.292

(0.527-1.299)

(0.491-2.002)

(0.607-2.753)

0.410

0.981

0.506

Male RF- (22)

23 (52.3)

21 (47.7)

5 (22.7)

13 (59.1)

4 (18.2)

1.172

0.510

1.255

(0.605-2.268)

(0.158-1.651)

(0.417-3.777)

0.638

0.261

0.686

Male ACPA+ (47)

40 (42.6)

54 (57.4)

8 (17.0)

24 (51.1)

15 (31.9)

0.792

1.076

1.800

(0.479-1.311)

(0.502-2.306)

(0.737-4.397)

0.365

0.850

0.197

Male ACPA- (18)

19 (52.8)

17 (47.2)

3 (16.7)

13 (72.2)

2 (11.1)

0.376

0.287

1.846

(0.207-0.686)

(0.062-1.336)

(0.491-6.946)

0.001

0.112

0.364

  1. *P < 0.05 versus controls; ACPA anti-citrullinated proteins antibodies; CI confidence interval CON healthy controls; OR Odds ratio RA rheumatoid arthritis; RF rheumatoid factor.